|
WO0230888A2
|
|
Tricyclic compounds and uses thereof
|
|
NZ520829A
|
|
Diphenylethylene compounds for treating diabetes and related conditions
|
|
US6624197B1
|
|
Diphenylethylene compounds
|
|
US6413504B1
|
|
Alpha-arylated cinnamic esters and 1,4-bis(alpha-carboxyl-beta-styryl)benzene esters an UV-blocking agents
|
|
US6525093B1
|
|
Compounds to treat diabetes and associated conditions
|
|
NZ511065A
|
|
Diphenylethylene (stillbenzenes) compounds for treating diabetes
|
|
CN1354659A
|
|
Novel diphenylethylene compounds
|
|
US6331633B1
|
|
Heterocyclic analogs of diphenylethylene compounds
|
|
US6245814B1
|
|
Diphenylethylene compounds
|
|
US6448450B1
|
|
1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
|
|
US6555702B2
|
|
Protein kinase inhibitor
|
|
CA2285452A1
|
|
Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes
|
